PRAXIS PRECISION MEDICINES, INC. Impairment of Long-Lived Assets Held-for-use
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-02-19
- PRAXIS PRECISION MEDICINES, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- PRAXIS PRECISION MEDICINES, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |